CN1533268A - 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物 - Google Patents

含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物 Download PDF

Info

Publication number
CN1533268A
CN1533268A CNA028056256A CN02805625A CN1533268A CN 1533268 A CN1533268 A CN 1533268A CN A028056256 A CNA028056256 A CN A028056256A CN 02805625 A CN02805625 A CN 02805625A CN 1533268 A CN1533268 A CN 1533268A
Authority
CN
China
Prior art keywords
compound
polymer
pharmaceutical composition
solid dispersion
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028056256A
Other languages
English (en)
Chinese (zh)
Inventor
N
N·巴特曼
J·卡希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1533268A publication Critical patent/CN1533268A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA028056256A 2001-02-27 2002-02-25 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物 Pending CN1533268A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0104752.1 2001-02-27
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN1533268A true CN1533268A (zh) 2004-09-29

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028056256A Pending CN1533268A (zh) 2001-02-27 2002-02-25 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物

Country Status (14)

Country Link
US (1) US20040138231A1 (cg-RX-API-DMAC7.html)
EP (1) EP1365746A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004527489A (cg-RX-API-DMAC7.html)
KR (1) KR20040011469A (cg-RX-API-DMAC7.html)
CN (1) CN1533268A (cg-RX-API-DMAC7.html)
BR (1) BR0206960A (cg-RX-API-DMAC7.html)
CA (1) CA2435815A1 (cg-RX-API-DMAC7.html)
GB (1) GB0104752D0 (cg-RX-API-DMAC7.html)
IL (1) IL156830A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006746A (cg-RX-API-DMAC7.html)
NO (1) NO20033782D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ527080A (cg-RX-API-DMAC7.html)
WO (1) WO2002067904A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305386B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2720851A1 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
LT2346495T (lt) * 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
KR20240124428A (ko) 2016-09-30 2024-08-16 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (cg-RX-API-DMAC7.html) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US6312726B1 (en) * 1993-08-20 2001-11-06 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
IL139406A (en) * 1998-05-02 2004-07-25 Astrazeneca Ab Heterocyclic derivatives inhibiting factor XA, pharmaceutical preparations containing them and their use as a drug in the treatment of diseases or conditions mediated by factor XA in warm-blooded animals
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺

Also Published As

Publication number Publication date
NZ527080A (en) 2005-02-25
WO2002067904A1 (en) 2002-09-06
ZA200305386B (en) 2004-10-11
BR0206960A (pt) 2004-03-09
CA2435815A1 (en) 2002-09-06
NO20033782L (no) 2003-08-26
KR20040011469A (ko) 2004-02-05
US20040138231A1 (en) 2004-07-15
MXPA03006746A (es) 2003-10-24
IL156830A0 (en) 2004-02-08
NO20033782D0 (no) 2003-08-26
JP2004527489A (ja) 2004-09-09
GB0104752D0 (en) 2001-04-18
EP1365746A1 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
CN105848647B (zh) 包含azd9291的药用组合物
US20200330600A1 (en) Pharmaceutical composition
CN103282036B (zh) 用于治疗骨髓纤维化的组合物和方法
KR20120029428A (ko) 아픽사반의 투여 형태
CA2793525C (en) Method for improving dissolution of anticoagulant agent
EP1381358B1 (en) Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
CN105232488B (zh) 一种含有利伐沙班的固体药物组合物
CN1533268A (zh) 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物
CN101951889A (zh) 伊马替尼组合物
CN102470109A (zh) 3-氰基喹啉片剂制剂及其应用
JP2022514569A (ja) 非晶質スパルセンタン組成物
JP7489370B2 (ja) ピラゾール－アミド化合物の非晶質固体分散体
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
JP2020529464A (ja) ３−フルオロ−４−［７−メトキシ−３−メチル−８−（１−メチル−１Ｈ−ピラゾール−４−イル）−２−オキソ−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル］−ベンゾニトリル含む医薬製剤
KR101282847B1 (ko) 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
EP2359816B1 (en) Aripiprazole formulations
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
AU2002233882A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
AU2007258325A1 (en) Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
EP4552633A1 (en) Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof
WO2025133629A1 (en) Tablet formulations involving alvelestat
WO2023128903A1 (en) Improved manufacturing method for formulations comprising amorphous tolvaptan
TW201300106A (zh) 治療ｈｃｖ感染之醫藥組合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication